NAVIGATOR

Tezepelumab in Severe, Uncontrolled Asthma

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 1,061 patients with severe uncontrolled asthma, tezepelumab 210 mg SC every 4 weeks reduced the annualised asthma exacerbation rate compared with placebo.

1 061

Schéma

Multicentre phase-3 RCT

Critère

Annualised asthma exacerbation rate

Pertinence

Résultat0.93 vs 2.10 (RR 0.44; 95% CI 0.37–0.53); benefit preserved in eosinophils <300/µL (RR 0.59).

Menzies-Gow A, et al. N Engl J Med. 2021;384(19):1800-1809. 10.1056/NEJMoa2034975

Discussion et critique

First biologic effective across all asthma phenotypes — including low-eosinophil disease; FDA-approved 2021.